{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:41:48Z","timestamp":1759970508343,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background\/objectives: The outcome of refractory\/relapsed systemic Anaplastic Large Cell Lymphoma (R\/R-sALCL), especially for anaplastic lymphoma kinase-1 (ALK-1)-negative disease, remains dismal even after autologous hematopoietic stem cell transplantation (AHSCT). The intensification of both salvage and conditioning regimens, without increasing the toxicity, could improve the outcome of AHSCT in R\/R-sALCL. Methods: Based on the successful experience of the incorporation of antiD20 monoclonal antibodies in the treatment of B-Cell Lymphomas, we designed a salvage and conditioning regimen incorporating the antiCD30-conjugated antibody (Brentuximab Vedotin, BV) to standard chemotherapy regimens, and we describe herein the clinical course of a patient with AKL-ve, R\/R-sALCL, who received salvage regimen BV + DHAP, followed by AHSCT with preparative regimen consisted of BV plus standard BEAM. Results: The novel regimen was well tolerated, and no severe adverse effects were noticed. The engraftment was prompt and successful. The patient remained in complete metabolic remission for almost 12 months post-transplant. Conclusions: The proposed treatment approach, which combines antiCD30-conjugated antibody with standard salvage and conditioning regimens, demonstrated a completely acceptable toxicity with promising efficacy.<\/jats:p>","DOI":"10.3390\/hematolrep17010003","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T09:11:13Z","timestamp":1737364273000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AntiCD30-Conjugated Antibody Plus Standard BEAM as Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Systemic Anaplastic Large Cell Lymphoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-041X","authenticated-orcid":false,"given":"Panayotis","family":"Kaloyannidis","sequence":"first","affiliation":[{"name":"Adult Haematology & Cellular Therapy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basmah","family":"Al-Charfli","sequence":"additional","affiliation":[{"name":"Adult Haematology & Cellular Therapy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biju","family":"George","sequence":"additional","affiliation":[{"name":"Adult Haematology & Cellular Therapy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7740-6963","authenticated-orcid":false,"given":"Charbel","family":"Khalil","sequence":"additional","affiliation":[{"name":"Adult Haematology & Cellular Therapy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour","family":"Al-Moghrabi","sequence":"additional","affiliation":[{"name":"Adult Haematology & Cellular Therapy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Nursing Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alfar","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firuz","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Odeh","sequence":"additional","affiliation":[{"name":"Hematopathology Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Daryahya","sequence":"additional","affiliation":[{"name":"Nursing Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Shabo","sequence":"additional","affiliation":[{"name":"Operations Department, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-S","article-title":"CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF","volume":"73","author":"Smith","year":"1993","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar","year":"2014","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/10428194.2020.1839658","article-title":"Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"112984","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: Results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Cozic","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2017.06.026","article-title":"Long-term outcomes of adults with first-relapsed\/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA\/SFGM-TC study","volume":"83","author":"Morel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41409-019-0734-7","article-title":"Autologous hematopoietic stem cell transplantation for relapsed\/refractory systemic anaplastic large cell lymphoma. a retrospective analysis of the lymphoma working party (LWP) of the EBMT","volume":"55","author":"Boumendil","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic malignancies: A review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/2040620717728000","article-title":"Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma","volume":"8","author":"Nikolaenko","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ejh.13568","article-title":"Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma","volume":"106","author":"Coppo","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1182\/bloodadvances.2022008524","article-title":"Salvage therapy with brentuximab-vedotin and bendamustine for patients with R\/R PTCL: A retrospective study from the LYSA group","volume":"7","author":"Aubrais","year":"2023","journal-title":"Blood Adv."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:32:12Z","timestamp":1759919532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/17\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["hematolrep17010003"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep17010003","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}